Legislative solutions to the prescription drug price issue were slow to materialize until the Inflation Reduction Act changed ...
AbbVie Inc. agreed to acquire ImmunoGen Inc. for a total equity value of $10.1 billion in a move aimed at gaining access to ...
The first 10 drugs included in the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act (IRA) were ...
Now at least one Philadelphia-area drugmaker is fighting back in the courts and on Capitol Hill. Merck, the biggest employer ...
Through the deal, AbbVie gains Elahere, which is approved for ovarian cancer patients who have received previous therapies, ...
We all know that policymakers are increasingly focused on lowering drug costs. From the Inflation Reductions Act's Medicare price negotiations (aka price controls) to the recent proposals directed at ...
Medicare’s drug price negotiation program violates the Constitution and must be struck down, Novartis Pharmaceuticals said in ...
In terms of therapeutic breakthroughs, Isasi suggested that the drug price negotiation program’s current structure is an effective deterrent from drugmakers’ low-impact profit chasing. “In ...
PHARMA FRETS OVER HIV DRUG LAWSUIT — The drug industry and its business allies warn that the outcome of a California lawsuit targeting a type of HIV medication could have a ripple effect on how ...
As consumers struggle with soaring drug prices, AstraZeneca Q3 profits doubled to $1.37 billion. The pharmaceutical industry is enjoying record profits while simultaneously pursuing lawsuits ...
There might just be a silver lining for Johnson & Johnson in the FDA's recent approval of Amgen’s Stelara biosimilar. That’s because the coming entry of a cheaper copycat presents J&J with an ...
AbbVie said on Thursday it will buy ImmunoGen for $10.1 billion, underscoring a growing interest from large drugmakers in a promising class of targeted cancer therapies. Through the deal, AbbVie gains ...
